Cardiac arrest caused by landiolol in a patient in thyroid crisis

• Published in: Journal of cardiology cases Vol. 14; no. 2; pp. 62 - 64
• Main Authors: Misumi, Kayo, MD, Kodera, Satoshi, MD, Nagura, Fukuko, MD, Kushida, Syunichi, MD, Shiojiri, Toshiaki, MD, Kanda, Junji, MD
• Format: Journal Article
• Language: English
• Published: Japan Elsevier Ltd 01.08.2016; Japanese College of Cardiology
• Subjects: Beta-blocker; Cardiac arrest; Cardiovascular; Landiolol; Thyroid crisis; Landiolol; Thyroid crisis; Beta-blocker; Cardiac arrest
• ISSN: 1878-5409; 1878-5409
• DOI: 10.1016/j.jccase.2016.04.002

Abstract In the acute phase of a thyroid crisis, the cardiovascular mortality rate is high and the likelihood of death and severity of heart failure increase significantly with an increasing heart rate. Thus, heart rate control is essential to avoid cardiac death. Propranolol has been used to manage thyroid crisis, but worsening heart failure and cardiac arrest have been previously reported when using propranolol in such cases. Thus, short-acting beta-blockers, such as landiolol and esmolol, are recommended, especially in patients with a low ejection fraction and severe heart failure. Our patient was a 49-year-old woman with a medical history of Graves’ disease, who stopped attending her control visits 1 year earlier. She presented with symptoms of heart failure, atrial fibrillation, and tachycardia. She was diagnosed with thyroid storm and low-ejection-fraction heart failure. After 2.5 h of treatment with landiolol, her heart suddenly arrested. Cardiopulmonary resuscitation was performed immediately and circulation was re-established. After receiving treatment for the thyroid crisis and heart failure, she was discharged without any sequelae. To the best of our knowledge, cardiac collapse caused by landiolol has not been previously reported. We wish to emphasize the importance of close hemodynamic monitoring when using landiolol in such cases. < Learning objective: Short-acting beta-blockers, such as landiolol, are used to treat thyroid crises. These agents are recommended because dose regulation is easy due to their short action and beta-1 selectivity. Our patient developed cardiac arrest when we attempted to treat the thyroid crisis with landiolol. This case suggests that landiolol might lead to cardiac arrest when used to treat patients in thyroid crisis who present with a concomitant hepatic disorder and low-ejection-fraction heart failure.>